Investment Rating - Buy (Maintained) [1] Core Views - The company's 24H1 performance met expectations, with significant growth in the IVD (In Vitro Diagnostics) business [2] - Revenue for 24H1 reached 20.53 billion yuan (+11.1%), with net profit attributable to the parent company at 7.56 billion yuan (+17.4%) [2] - The IVD business grew by 28.2% in 24H1, driven by strong demand in both domestic and international markets [2] - The company continues to invest heavily in R&D, with 1.78 billion yuan spent in 24H1, focusing on high-end product innovation and expanding the "Ruizhilien" ecosystem [2] Business Performance Life Information & Support - Revenue for 24H1 was 8.01 billion yuan (-7.6%), with significant growth in minimally invasive surgery and high-value consumables [2] - Domestic market faced delays due to healthcare industry reforms, but international demand has recovered, leading to double-digit growth [2] In Vitro Diagnostics (IVD) - Revenue for 24H1 was 7.65 billion yuan (+28.2%), with chemical发光业务增长超过30% [2] - Domestic IVD business grew over 25%, with blood cell business growing over 30% [2] - International IVD business grew over 30%, with successful penetration into over 60 overseas third-party laboratories [2] Medical Imaging - Revenue for 24H1 was 4.27 billion yuan (+15.5%), with high-end ultrasound models growing over 40% [2] - Domestic market faced challenges due to industry reforms, but the company increased investment in high-end international markets [2] Financial Projections - Expected net profit attributable to the parent company for 2024-2026 is 13.75 billion, 16.65 billion, and 19.95 billion yuan, respectively [2] - EPS for 2024-2026 is projected to be 11.34, 13.73, and 16.45 yuan, with PE ratios of 22, 18, and 15 times, respectively [2] Market Performance - The stock's relative performance compared to the CSI 300 index shows a decline of 16% over the past year [4] - The company's total market capitalization is 300.07 billion yuan, with a total asset value of 60.63 billion yuan [5]

[Table_StockInfo] 2024 年 09 月 06 日 证券研究报告•2024 年中报点评 当前价：13.76 元 隆基绿能（601012）电力设备 目标价：——元（6 个月） 计提大额资产减值，BC 组件出货顺利 [Table_Summary 事件：公司 2024]H1 实现营业收入 385.29 亿元，同比下降 40.41%；实现归母 净利润-52.43亿元，同比下降 157.13%。2024Q2实现营业收入 208.55亿元， 同比下降 42.60%；实现归母净利润-28.99 亿元，同比下降 152.21%。 受产业链价格持续大幅下降和存货减值计提影响，上半年业绩大幅亏损。面对 产业深度调整期的剧烈波动，公司积极调整产销节奏，2024年上半年实现硅片 出货量 44.44GW（对外销售 21.96GW）；电池对外销售 2.66GW；组件出货量 31.34GW，其中亚太区域销量同比大幅增长超 140%。光伏产品实现营业收入 367.08 亿元，毛利率仅 6.46%。受产业链价格持续大幅下降和存货减值计提影 响，公司 2024H1 业绩出现较大亏损。上半年公司计提资产减值准备 57.84 亿 ...

Investment Rating - The report maintains a "Buy" rating for the company [1][2] Core Views - The company reported a revenue of 4.165 billion yuan in H1 2024, a year-on-year increase of 1.14%, with a net profit loss of 119 million yuan, which represents a 66.59% reduction in losses compared to the previous year [1] - In Q2 2024, the company achieved a revenue of 2.169 billion yuan, a year-on-year increase of 1.72%, and a net profit of 38.24 million yuan, marking a 115.19% increase compared to the same period last year [1] - The company sold 1.3364 million pigs in H1 2024, a 15.9% increase year-on-year, and the overall pig slaughtering volume reached 2.1128 million pigs, generating 3.934 billion yuan in revenue from slaughtering and meat processing, a 4.06% increase year-on-year [1][2] - The report highlights a continuous decline in breeding costs and an increase in production efficiency, contributing to improved profitability [2] Summary by Relevant Sections Financial Performance - The company’s total revenue for 2024 is projected to be 8.578 billion yuan, with a growth rate of 54.69% [3] - The net profit for 2024 is expected to be 657 million yuan, reflecting a growth rate of 208.69% [3] - The earnings per share (EPS) for 2024 is projected at 1.06 yuan, with a dynamic PE ratio of 10 times [3] Industry Insights - The national pig output decreased by 3.1% year-on-year, with a total of 36.395 million pigs slaughtered in the first half of 2024 [1] - The price of pigs has shown a steady increase from 15 yuan/kg in April to 20 yuan/kg in August 2024 due to capacity reduction in the industry [1] - The company is expanding its breeding capacity through a light-asset model and has a current fattening capacity of 3.1 to 3.3 million pigs [2]

Investment Rating - The report maintains a "Buy" rating for the company with a target price of 22.14 CNY over the next six months [1][11]. Core Views - The company has successfully turned its pig farming business from loss to profit, while the leather business has negatively impacted overall profits. The reduction in costs and the increase in pig sales prices have contributed to this turnaround [4][5]. - The company is expected to see significant growth in revenue and profit over the next few years, with projected EPS of 1.41 CNY in 2024, 2.34 CNY in 2025, and 2.86 CNY in 2026 [3][5]. Summary by Sections Financial Performance - In H1 2024, the company achieved a revenue of 2.233 billion CNY, a year-on-year increase of 13.13%, and a net profit attributable to the parent company of -0.045 billion CNY, reducing losses by 87.13% [4]. - The company sold 1.0945 million pigs in H1 2024, with a significant increase in the sale of commercial pigs by 24.69% year-on-year [4]. Revenue and Profit Forecast - The company forecasts revenues of 6.073 billion CNY in 2024, 8.472 billion CNY in 2025, and 10.095 billion CNY in 2026, with growth rates of 50.28%, 39.52%, and 19.15% respectively [3][10]. - The net profit attributable to the parent company is expected to be 0.717 billion CNY in 2024, 1.196 billion CNY in 2025, and 1.458 billion CNY in 2026, reflecting growth rates of 211.09%, 66.80%, and 21.90% respectively [3][10]. Cost Management and Operational Efficiency - The company has implemented effective cost management strategies, achieving a PSY (Pigs per Sow per Year) of over 29 and reducing feed-to-meat ratios to below 2.6, which has significantly lowered production costs [5]. - The cost of raising commercial pigs was reported at 6.44 CNY per jin in June 2024 and 6.35 CNY per jin in July 2024, with total costs remaining below 7 CNY per jin [5]. Market Position and Competitive Advantage - The company is positioned to benefit from ongoing industry capacity reductions, which have led to rising pig prices, with prices increasing from 15 CNY per kg in April to 20 CNY per kg by August 2024 [4][5]. - The company has a robust breeding program with over 240,000 breeding pigs, ensuring sustained growth in production capacity [4].

[ T able_StockInfo] 2024 年 09 月 03 日 证券研究报告•2024 年中报点评 买入 （维持） 当前价：10.97 元 华统股份（002840）食品饮料 目标价：——元（6 个月） Q2 实现盈利，成本稳步下降 [Table_Summary 业绩总结：公司发布] 2024年中报。2024H1公司营收 41.65亿元，同比增 1.14%， 归母净利润为亏损 1.19亿元，同比减亏 66.59%。其中 Q2实现营业收入为 21.69 亿元，同比增 1.72%，归母净利为3824.02 万元，同比增 115.19%。 点评：降本增效叠加景气上升，Q2 实现盈利。2024 年上半年公司共销售生猪 133.64 万头，生猪销售量较去年同期增长 15.9%；公司共计屠宰生猪 211.28万 头，屠宰及肉类加工业务实现营业收入 39.34亿元。报告期内，全国生猪价格整 体呈现震荡上涨走势，公司商品猪销售价格逐月上涨。此外，仔猪成本、饲料成 本下降，产能利用率提升，养殖成本降低，盈利能力得到显著改善，报告期内公 司亏损金额较上年同期有明显下降。 行业产能去化持续兑现，负债率限制产能增长。上半年， ...

[ T able_StockInfo] 2024 年 09 月 04 日 证券研究报告•2024 年中报点评 持有 （维持） 当前价：16.80 元 天合光能（688599）电力设备 目标价：——元（6 个月） 光储协同发展，逆境彰显韧性 [Table_Summary 事件：公司 2024H1 ] 实现营业收入 429.68 亿元，同比下降 12.99%；实现归母 净利润 5.26亿元，同比下降 85.14%。2024Q2实现营业收入 247.12 亿元，同 比下降 11.95%；实现归母净利润 0.10 亿元，同比下降99.41%。 组件出货延续增长，毛利率继续承压。2024H1公司组件出货量为 34GW，同比 增长超过 25%。其中 2024Q2组件出货约 20GW，环比 2024Q1有 40%以上增 长。受制于产业链供需失衡、光伏产品市场价格大幅下降的影响，公司组件业务 盈利能力有所下降。2024H1组件毛利率为 11.13%，同比下降 5.52pp。2024Q1、 2024Q2 组件毛利率分别为 13.34%、9.49%，毛利率继续承压。 支架、分布式系统、光伏电站、储能协同发展，业绩彰显韧性。得益于 ...

[ T able_StockInfo] 2024 年 09 月 04 日 证券研究报告•2024 年中报点评 当前价： 10.33 元 晶澳科技（002459）电力设备 目标价： ——元（6 个月） 亏损有所收窄，经营性现金流转正 [Table_Summary 事件：公司 2024H1 ] 实现营业收入 373.57 亿元，同比下降 8.54%；实现归 母净利润-8.74 亿元，同比下降 118.16%。2024Q2 实现营业收入 213.85 亿 元，同比增长 5.02%；实现归母净利润-3.91 亿元，同比下降 117.54%。 2024Q2 毛利率继续承压，出货量环比增长亏损有所收窄。2024H1 公司电 池组件出货量超 38GW（含自用 1GW），其中组件海外出货量占比约 54%。 光伏组件业务实现营业收入 353.21 亿元，同比下降 9.99%；毛利率 4.53%， 同比降低 14.13pp。上半年组件销售均价 0.95 元/W，单位毛利 0.04 元/W。 2024Q2 公司电池组件出货量 21.94GW，其中自用 472MW，2024Q2 出货 量环比增长 36.63%。2024Q2 公司综合 ...

Investment Rating - The report maintains a "Buy" rating for the company with a target price of 22.14 CNY over the next six months [1][11]. Core Insights - The company has successfully turned its pig farming business from loss to profit, while the leather business has negatively impacted overall profits. The pig farming segment has seen a reduction in costs and an increase in sales prices, leading to a significant recovery in profitability [2][3]. - The report highlights that the company has achieved a revenue of 2.233 billion CNY in H1 2024, representing a year-on-year increase of 13.13%. The net profit attributable to the parent company has improved by 87.13% year-on-year, with a net profit of -45 million CNY [2][3]. - The report emphasizes the ongoing capacity reduction in the industry, which has led to a rise in pig prices from 15 CNY/kg in April to 20 CNY/kg by August 2024 [2][3]. Summary by Sections Financial Performance - In H1 2024, the company sold 1.0945 million pigs, with a year-on-year increase of 24.69% in the number of market pigs sold. The revenue from pig products reached 2.039 billion CNY, up 22.56% year-on-year [2][3]. - The company’s breeding project has been delivered, and several other breeding farms are expected to be operational in the second half of 2024, which will support further growth in pig farming capacity [2][3]. Cost Management - The company has implemented a dual approach of "technology + management" to enhance production management and reduce costs. Key production indicators such as PSY (Pigs per Sow per Year) have improved, reaching above 29, while the feed-to-meat ratio has decreased to below 2.6 [3]. - The cost of raising market pigs was reported at 6.44 CNY/kg in June and 6.35 CNY/kg in July, with total costs remaining below 7 CNY/kg [3]. Earnings Forecast - The earnings per share (EPS) for 2024-2026 are projected to be 1.41 CNY, 2.34 CNY, and 2.86 CNY, respectively, with corresponding dynamic price-to-earnings (PE) ratios of 13, 8, and 6 times [3][4]. - The report anticipates a significant increase in revenue, with projections of 4.041 billion CNY in 2024, 6.073 billion CNY in 2025, and 8.472 billion CNY in 2026, reflecting growth rates of 50.28% and 39.52% for the following years [4][10].

Investment Rating - The report maintains a "Buy" rating for the company with a target price of 120.68 CNY over the next six months [1][3]. Core Insights - The company achieved a revenue of 8.32 billion CNY in the first half of 2024, representing a year-on-year growth of 37.9%, and a net profit attributable to shareholders of 990 million CNY, up 108.3% year-on-year [2]. - The gross margin for the first half of 2024 was 26.2%, an increase of 3.3 percentage points year-on-year, while the net profit margin rose by 4.0 percentage points to 11.9% [2]. - The company is focusing on high-value products such as AI servers and high-end communication boards, which are expected to drive profitability [2]. - The report highlights the scarcity of capacity in the data communication sector and the ongoing improvement in profit structure [2]. Summary by Sections Performance Summary - In H1 2024, the company reported revenue of 8.32 billion CNY, a 37.9% increase year-on-year, and a net profit of 990 million CNY, reflecting a 108.3% growth [2]. - The gross margin improved to 26.2%, and the net profit margin reached 11.9%, indicating enhanced profitability [2]. Business Outlook - The company is expected to benefit from the increasing demand for AI servers and high-end communication products, which will positively impact the PCB business [2]. - The report anticipates a steady increase in production capacity and sales for the ABF substrate project over the next 3-5 years, potentially generating over 6 billion CNY in revenue [2][3]. Financial Projections - The projected earnings per share (EPS) for 2024-2026 are 4.31 CNY, 5.06 CNY, and 5.92 CNY, respectively, with corresponding price-to-earnings (PE) ratios of 23x, 19x, and 16x [3][10]. - The company is expected to achieve a compound annual growth rate (CAGR) of 29.5% in net profit over the next three years [3].

Investment Rating - Buy (First Coverage) with a target price of HKD 5.51 [1] Core Views - Fufeng Group is a global leader in biological fermentation with a diversified product portfolio, including food additives, animal nutrition, high-end amino acids, and colloids [7] - The company faces short-term profitability pressure due to declining revenue and net profit in H1 2024, primarily driven by reduced income from colloids and other segments [2] - Despite challenges, the company maintains a stable revenue base in food additives and animal nutrition, with high-end amino acids showing strong growth potential [2][12] Business Performance - H1 2024 revenue decreased by 1.6% YoY to RMB 13.37 billion, with net profit declining by 32.3% YoY to RMB 1.04 billion [2] - Food additives and animal nutrition segments contributed 51.7% and 31.4% of total revenue, respectively, while high-end amino acids grew by 29.9% YoY [2] - Gross margin dropped by 5.1 percentage points to 17.2%, mainly due to lower profitability in colloids and other segments [2][16] Segment Analysis - **Food Additives**: Revenue increased by 5.5% YoY to RMB 6.92 billion, but gross margin fell by 3.8 percentage points to 11.0% due to lower MSG prices [2][16] - **Animal Nutrition**: Revenue grew by 2.5% YoY to RMB 4.20 billion, with gross margin improving by 5.9 percentage points to 20.4% driven by threonine and lysine price increases [2][16] - **High-End Amino Acids**: Revenue surged by 29.9% YoY to RMB 1.08 billion, with gross margin slightly up by 0.7 percentage points to 36.8% [2][16] - **Colloids**: Revenue dropped by 44.9% YoY to RMB 900 million, with gross margin plunging by 21.9 percentage points to 39.2% due to a 48.2% decline in xanthan gum prices [2][16] Geographic Expansion - Domestic revenue accounted for 73.1% of total revenue in 2023, growing by 4.9% YoY, while overseas revenue declined by 5.4% [17] - The company plans to establish production bases in the US and Eastern Europe for threonine and lysine to mitigate geopolitical risks and improve supply chain efficiency [17] Cost Control - Sales and management expense ratios remained stable at 6.9% and 3.5%, respectively, in H1 2024 [2][20] - The company aims to optimize logistics and reduce unit transportation costs to further lower expense ratios [20] Financial Projections - Net profit is expected to grow to RMB 2.19 billion, RMB 3.23 billion, and RMB 4.32 billion in 2024, 2025, and 2026, respectively [3] - EPS is projected to be RMB 0.87, RMB 1.28, and RMB 1.71 for 2024, 2025, and 2026 [3] Valuation - The company is valued at 4x 2025 earnings, translating to a target price of HKD 5.51 based on a 0.93:1 exchange rate [3]